Nutra Pharma’s Chairman and CEO, Rik J Deitsch, has been interviewed for the Pharmaceutical Issue of the Wall Street Transcript. In the interview, Mr. Deitsch discusses the company’s recent accomplishments, its upcoming launch of Cobroxin, and its future growth opportunities.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J Deitsch, has been interviewed for the Pharmaceutical Issue of The Wall Street Transcript.
“With the impending launch of our first biopharmaceutical product, Cobroxin, and our transition from a research and development stage biotechnology company into a revenue-producing company, it is now more important than ever that we share our story with the investment community,” explained Mr. Deitsch. “As a highly-respected financial publication, The Wall Street Transcript provides the perfect outlet to communicate with retail and institutional investors,” he added.
In the interview, Mr. Deitsch discusses Nutra Pharma's launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain. In addition, he outlines the company’s recent accomplishments and the company’s growth opportunities with its drug discovery pipeline and potential strategic acquisitions.
The Wall Street Transcript is one of the country’s leading financial publications, reaching over 200,000 readers each month through its website and its printed magazine. Its subscriber base represents some of the top money managers, investment brokers, and corporations in the United States. The Pharmaceutical Issue, which features the interview with Mr. Deitsch, will be published and available in November 2009.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Rik J. Deitsch’s interview in the Pharmaceutical Issue of the Wall Street Transcript should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.